<\/strong><\/h2>\n\n\n\n1\u3001Di X, Li Y, Wei J, Li T, Liao B. Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies. Adv Sci (Weinh). 2025 Jan;12(3):e2410416.<\/p>\n\n\n\n
2\u3001Liu Z, Wei S, Li Y, et al. Protein phosphatase 6 regulates metabolic dysfunction-associated steatohepatitis via the mTORC1 pathway. J Hepatol. 2025 Sep;83(3):630-642.<\/p>\n\n\n\n
3\u3001Vandyck K, McGowan DC, Deval J, et al. Discovery and Preclinical Profile of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta (THR-\u03b2) Agonist for the Treatment of MASH. J Med Chem. 2024 Sep 12;67(17):14840-14851.<\/p>\n\n\n\n
4\u3001Noureddin M, Rinella ME, Yale et al. Efruxifermin in Compensated Liver Cirrhosis Caused by MASH. N Engl J Med. 2025 Jun 26;392(24):2413-2424.<\/p>\n\n\n\n
5\u3001Noureddin M, Frias JP, Yale K\uff0cet al. Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet. 2025 Aug 16;406(10504):719-730.<\/p>\n\n\n\n
6\u3001Loomba R, Kowdley KV, Odrljin T,et al. Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial. Lancet Gastroenterol Hepatol. 2025 Aug;10(8):734-745.<\/p>\n\n\n\n
7\u3001Loomba R, Sanyal AJ, Abdelmalek MF, et al. Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH. N Engl J Med. 2023 Sep 14;389(11):998-1008.<\/p>\n\n\n\n
8\u3001Xiang L, Wang G, Ding Y, et al. Safety and efficacy of GLP-1\/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study. J Hepatol. 2025 Jun;82(6):967-978.<\/p>\n\n\n\n
9\u3001Francque SM, Bedossa P, Abdelmalek MF, et al. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. N Engl J Med. 2021 Oct 21;385(17):1547-1558.<\/p>\n\n\n\n
10\u3001Sun Y, Wu C, You H, et al. Chiglitazar in MASLD with hypertriglyceridemia and insulin resistance: A phase II, randomized, double-blind, placebo-controlled study. Hepatology. 2025 Jul 28.<\/p>\n\n\n\n
11\u3001Loomba R, Hartman ML, Sanyal AJ, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024 Jul 25;391(4):299-310.<\/p>\n\n\n\n
11\u3001Xie Z, Cheng L, Li J, et al. The enedioic acid analog 326E alleviates metabolic dysfunction-associated steatohepatitis via dual targeting at ACLY and PPAR\u03b1. Cell Metab. 2025 Nov 4;37(11):2149-2166.e9.<\/p>\n\n\n\n
12\u3001Ratziu V, Harrison SA, Scalfaro P, et al. Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH. J Hepatol. 2023 Mar;78(3):479-492. Epub 2022 Nov 9.<\/p>\n\n\n\n
13\u3001Ratziu V, Yilmaz Y, Sanyal AJ, et al. Aramchol improves hepatic fibrosis in metabolic dysfunction-associated steatohepatitis: Results of multimodality assessment using both conventional and digital pathology. Hepatology. 2025 Mar 1;81(3):932-946.<\/p>\n\n\n\n
14\u3001Hu Y, Li H, Ding Y, et al. ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib\/IIa trial. Nat Commun. 2023 Oct 12;14(1):6409.<\/p>\n\n\n\n
15\u3001Wong VW, Neff GW, Gunn N, et al. HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study. Clin Mol Hepatol. 2025 Jul;31(3):1071-1083.Epub 2025 Apr 21.<\/p>\n\n\n\n
16\u3001Loomba R, Bedossa P, Harrison SA, et al. Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol. 2024 Dec;9(12):1090-1100. Epub 2024 Oct 11.<\/p>\n\n\n\n
17\u3001Wang H, Zhang J, Chai J, et al. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk\/-Egr-1 signaling and Tgf\u03b21\/Smad pathway in mice. Biochim Biophys Acta Mol Basis Dis. 2022 Dec 1;1868(12):166556.<\/p>\n\n\n\n
18\u3001Resmetirom\u8bc4\u5ba1\u62a5\u544a<\/p>\n\n\n\n
19\u3001\u53f8\u7f8e\u683c\u9c81\u80bd\u8bc4\u5ba1\u62a5\u544a<\/p>\n\n\n\n
20\u3001\u5404\u4e2a\u836f\u7269\u7814\u53d1\u516c\u53f8\u7684\u5b98\u7f51\u3001\u516c\u4f17\u53f7\u3001\u5e74\u62a5\u7b49<\/p>\n\n\n\n
21\u30012025\u5e74AASLD\u5927\u4f1a\u7b49<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/p>\n\n\n\n
\u64b0\u7a3f\u4eba\uff1a\u9648\u798f\u9f0e<\/p>\n\n\n\n
\u5ba1\u6838\uff1a\u9648\u4e9a\u7ea2<\/p>\n\n\n\n
\u6da6\u8272\u6392\u7248\uff1a\u5468\u5b89\u6960<\/p>\n\n\n\n
<\/p>\n","protected":false},"excerpt":{"rendered":"
2025\u5e74\uff0c\u809d\u7ea4\u7ef4\u5316\u521b\u65b0\u836f\u8fce\u6765”\u7cbe\u51c6\u9776\u5411+\u8054\u5408\u5e72\u9884”\u65f6\u4ee3\u3002\u672c\u6587\u76d8\u70b9\u745e\u53f8\u7f8e\u66ff\u7f57\u4e0e\u53f8\u7f8e\u683c\u9c81\u80bd\u4e24\u5927\u65b0\u836f\uff0c\u89e3\u6790THR-\u03b2\u3001FGF21R\u3001GLP-1R\u3001PPAR\u7b49\u4e3b\u8981\u9776\u70b9\u7ade\u4e89\u683c\u5c40\uff0c\u5e76\u4ecb\u7ecd\u4e59\u809d\u809d\u7ea4\u7ef4\u5316\u3001FASN\u6291\u5236\u5242\u7b49\u5dee\u5f02\u5316\u7a81\u7834\u8def\u5f84\u3002<\/p>\n","protected":false},"author":1,"featured_media":1644,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[90,91,72,77,92,89,35,86,15,88,32,85,87,69],"class_list":["post-1643","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-fgf21r","tag-glp-1r","tag-mash","tag-masld","tag-ppar","tag-thr-","tag-35","tag-86","tag-15","tag-88","tag-32","tag-85","tag-87","tag-69"],"_links":{"self":[{"href":"https:\/\/www.millibuff.com\/index.php?rest_route=\/wp\/v2\/posts\/1643","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.millibuff.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.millibuff.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.millibuff.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.millibuff.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1643"}],"version-history":[{"count":3,"href":"https:\/\/www.millibuff.com\/index.php?rest_route=\/wp\/v2\/posts\/1643\/revisions"}],"predecessor-version":[{"id":1649,"href":"https:\/\/www.millibuff.com\/index.php?rest_route=\/wp\/v2\/posts\/1643\/revisions\/1649"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.millibuff.com\/index.php?rest_route=\/wp\/v2\/media\/1644"}],"wp:attachment":[{"href":"https:\/\/www.millibuff.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1643"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.millibuff.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1643"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.millibuff.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1643"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"\u5c0f\u725b\u6d1e\u5bdf](\"http:\/\/www.millibuff.com\/wp-content\/uploads\/2026\/01\/\u7a3f\u5b9a\u8bbe\u8ba1-2.jpg\")
<\/figure>\n\n\n\n![\"\"](\"https:\/\/www.millibuff.com\/wp-content\/uploads\/2026\/01\/\u7b2c\u4e09\u671f\u63d2\u56fe1.png\")
<\/figure>\n\n\n\n